Head: Prof. Laurence Lovat
The UCL Gastroenterological Intervention Centre (GENIE) works to develop novel, minimally invasive approaches to managing diseases of the oesophagus, stomach and bowel.GENIE pioneered endoscopic therapy for pre-cancerous changes and early cancer of the oesophagus. In particular, the Centre introduced HALO radiofrequency ablation (RFA) for dysplastic (pre-cancerous) Barrett’s oesophagus to the UK and now heads the largest registry of this treatment in Europe. GENIE also develops endoscopic diagnostic and therapeutic tools, including diagnostic imaging, ‘virtual’ biopsy, biomarkers of cancer risk and a whole range of novel therapies. The Centre staff collaborate widely with leading research and patient groups throughout the UK and internationally to develop these new ideas.
- Development of novel endoscopic procedures.
- Risk stratification of pre-cancerous conditions and oesophageal cancer.
- Identification of biomarkers for therapeutic application and diagnosis of GI tract disease.
- Development of Augmented and Virtual Reality systems for minimally-invasive Colorectal Cancer Surgery
- Investigation of complex imaging modalities to predict response to chemoradiotherapy
- The use of fluorescence imaging to guide oncological GI surgery
- Saliva to Predict rIsk of disease using Transcriptomics and Epigenetics (SPIT)
- Duodenal Muscosal Resurfacing (DMR)
- UK HALO Radiofrequency Ablation Registry
- FLICC and FLICC II (Fluorescence lymphangiography in colorectal cancer)
- Laparoscopic versus robotic complete mesocolic excision (CME) for right-sided colorectal cancer
- The use of fluorescence imaging to identify rectal cancer
- TIPS Study
- The VERDICT Study for Rectal Cancer
- The INTACT Study